Expansion of Newborn Bloodspot Screening Public Consultation
Overview
The Australian Government has committed $39.0 million over four years to expand newborn bloodspot screening (NBS) to include more conditions and ensure consistency of programs across Australia.
This consultation process will give the Department of Health and Aged Care important information about the range of issues that should be considered during implementation of expansion.
For context about the newborn bloodspot screening programs, and the expansion process, you may wish to view the consultation paper provided below, prior to responding to the consultation questions.
Consultation Information
How to respond:
- If you wish to view the consultation paper before responding to the consultation questions:
- You can access the paper by right clicking the 'Newborn Bloodspot Screening Consultation Paper' link, which is found under 'Related' at the bottom of this page.
- Right click, and select 'Open in new tab' to read the document.
- To respond to the consultation questions, using the link below click 'Submit your response'.
- This button will take you to a link to the consultation questions. Click this link to open the consultation questions.
- Once the consultation questions are completed, click submit in the bottom right corner.
You can provide your responses to the consultation questions from Friday 11 November, closing 11:59PM AEDT Monday 12 December 2022.
Responses are captured through the consultation questions. It has 11 questions with an additional set of questions based on what group of people are responding (consumers or clinicians or other groups) and should take between 15 and 30 minutes to complete.
Please contact NBS@health.gov.au if you have any questions or concerns.
Why your views matter
Your response to the consultation questions and consultation paper aims to ensure your views are included, heard and recognised, and used to inform the expansion of NBS.
Audiences
- Anyone from any background
Interests
- Children's health
Share
Share on Twitter Share on Facebook